VivoSim Labs Unveils Advanced Toxicology Platform at EUROTOX 2026

SAN DIEGO, Sept. 16, 2026 /CourierPR/ -- VivoSim Labs, a company focused on providing testing of drugs and drug candidates in three-dimensional human tissue models, has unveiled new data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria. The findings demonstrate the company's NAMkind™ platform's ability to predict drug toxicity across a range of therapies, including small molecules and antibody-drug conjugates (ADCs).

The new data, presented by VivoSim, highlights the company's NAMkind™ Liver and Intestine platforms, which support long-duration testing of human cells. The Liver platform can maintain liver spheroid viability for up to 28 days, while the Intestine models can maintain barrier integrity for up to three weeks. These extended cultures allow researchers to evaluate repeat-dose effects that shorter-duration assays might miss.

At EUROTOX, VivoSim showcased how its NAMkind™ platform can successfully rank clinical safety risks for small-molecule reference compounds and deconvolute complex structural toxicities in advanced ADC modalities. For instance, the platform ranked trastuzumab deruxtecan as significantly more hepatotoxic than trastuzumab emtansine. In the Intestine model, transepithelial electrical resistance (TEER) identified mucosal barrier deterioration before overt tissue cytotoxicity, with human ileum tissue demonstrating greater sensitivity to ADC-induced toxicity than colon tissue.

These findings are particularly significant as ADC development expands across oncology and other therapeutic areas. The ability to identify and differentiate toxicity risks earlier in the development process can save years of development time and millions of dollars in potential clinical failures. As global regulators, including the U.S. Food and Drug Administration (FDA), continue to advance frameworks for New Approach Methodologies (NAMs) and human-relevant alternatives to traditional animal testing, VivoSim's technology is poised to play a crucial role in the pharmaceutical industry.

Keith Murphy, Executive Chairman of VivoSim Labs, emphasized the importance of the company's technology in the context of regulatory shifts.

Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs, added, "Predicting organ-specific toxicity requires capturing the biology of chronic, repeat-dose exposure. With our extended-culture platforms, we observe micro-architectural and functional degradation that traditional short-term assays may miss. Whether ranking clinical DILI risk across small-molecule analogs or pinpointing why trastuzumab deruxtecan exhibits distinct hepatic and ileal liabilities compared to emtansine, our multi-endpoint profiling gives biopharma teams human-relevant translational signatures to optimize compound selection and de-risk pipelines."

The EUROTOX presentation marks a meaningful validation point in VivoSim's commercial thesis. The company's ability to evaluate both traditional small molecules and increasingly important complex modalities such as ADCs positions its NAMkind™ platform to broaden its applications across pharmaceutical R&D. As VivoSim continues to refine its technology and expand its market reach, it is well-positioned to support the growing demand for human-relevant predictive toxicology methods in the pharmaceutical industry.